DaVita (DVA) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• DaVita (NYSE:DVA) is set to announce its Q2 2025 earnings on August 5th, with analysts predicting earnings of $2.70 per share and revenue of $3.36 billion.
• The company reported a 5% revenue increase year-over-year in its last earnings announcement, posting an EPS of $2.00 against estimates of $1.75.
• DaVita's current market capitalization stands at $10.98 billion, with insiders holding only 2% of the stock, while institutional investors own approximately 90.12%.

DaVita (NYSE:DVA - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 5th. Analysts expect DaVita to post earnings of $2.70 per share and revenue of $3.36 billion for the quarter. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.25. The firm had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The business's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.26 EPS. On average, analysts expect DaVita to post $11 EPS for the current fiscal year and $13 EPS for the next fiscal year.

DaVita Stock Down 0.9%

Shares of NYSE:DVA traded down $1.27 during trading on Wednesday, hitting $144.71. 627,996 shares of the company were exchanged, compared to its average volume of 679,834. The company has a current ratio of 1.25, a quick ratio of 1.20 and a debt-to-equity ratio of 23.18. The stock has a market cap of $10.93 billion, a price-to-earnings ratio of 14.34, a P/E/G ratio of 1.01 and a beta of 1.11. DaVita has a fifty-two week low of $131.76 and a fifty-two week high of $179.60. The firm has a fifty day moving average price of $140.40 and a two-hundred day moving average price of $148.20.

Analyst Ratings Changes

DVA has been the topic of a number of recent analyst reports. Truist Financial decreased their target price on DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a report on Monday, May 19th. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $167.40.

Insider Transactions at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 2.00% of the stock is owned by company insiders.

Institutional Trading of DaVita

An institutional investor recently raised its position in DaVita stock. Goldman Sachs Group Inc. grew its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 19.1% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 179,140 shares of the company's stock after acquiring an additional 28,739 shares during the quarter. Goldman Sachs Group Inc. owned about 0.24% of DaVita worth $27,403,000 as of its most recent SEC filing. Institutional investors own 90.12% of the company's stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.